BioNTech
clinical program to assess safety tolerability and immunogenicity of an omicron adapted vaccine lata | BioNTech
Company
Deck Type
Sector
Industry
Deck date
March 2022
Slide
16 of 37
Related slides by other companies
Ocuphire Pharma
Investor Day
January 2022
phase clinical trials data supporting the zeta trial rat aches high levels in rat eye is orally | Ocuphire Pharma
Immatics
Investor Presentation
November 2023
phase clinical trial to evaluate targeting | Immatics
Valneva
IPO
April 2021
the only inactivated vaccine in clinical development in with | Valneva
Kymera
Investor Day
December 2021
clinical study design and objectives | Kymera
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Investor Day
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights